You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥(06855.HK)料未來5年為藥品商業化高峰期
阿思達克 10-28 10:21

亞盛醫藥(06855.HK)今日在主板上市,聯合創始人兼首席執行官楊大俊在上市儀式後表示,公司有8項處臨床階段的小分子候選藥物,其中核心藥物「HQP1351」的關鍵二期臨床試驗持續,公司計劃明年為該藥申請上市註冊許可,如臨床數據滿意及獲監管批准,最快可於2021年商業化,至於其他藥品的商業化高峰期預期在未來5年。

公司是次上市引入中生製藥(01177.HK)作為基石投資者,認購相當於2,000萬美元股份。楊大俊稱未來與中生有很多機會探討合作空間,但是次對方是以投資者身份入股。對於內地近年持續調整對醫藥行業的政策,他指國家醫藥政策為支持創新藥,政策調控主要針對仿製藥,相信公司研發的藥品會有很好保證。 ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account